Zhen Liu

Dr. Zhen Liu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZLZhen Liu
Zhen Liu
JGJunling Gao
Junling Gao
YBYuxuan Ban
Yuxuan Ban
TWTing Ting Wan
Ting Ting Wan
WSWenjuan Song
Wenjuan Song
YTYuou Teng
Yuou Teng

1 August 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHongyu Liu
Hongyu Liu
QFQingshan Fu
Qingshan Fu
YLYao Lu
Yao Lu
WZWenqiang Zhang
Wenqiang Zhang
PYPeng Yu
Peng Yu
XSXiaosheng Sun
Xiaosheng Sun

12 September 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZhen Liu
Zhen Liu
YYYajie Yuan
Yajie Yuan
NWNing Wang
Ning Wang
PYPeng Yu
Peng Yu
YTYuou Teng
Yuou Teng

9 February 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JGJunling Gao
Junling Gao
NWNing Wang
Ning Wang
WSWenjuan Song
Wenjuan Song
YYYajie Yuan
Yajie Yuan
YTYuou Teng
Yuou Teng
ZLZhen Liu
Zhen Liu

1 February 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZLZhen Liu
Zhen Liu
QFQingshan Fu
Qingshan Fu
YWYu Wang
Yu Wang
LCLi Cui
Li Cui
WZWenqiang Zhang
Wenqiang Zhang
PYPeng Yu
Peng Yu
Currently, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR mutation. However, some lung cancer patients fail to respond and eventually develop drug resistance. Therefore, new therapeutic strategies are needed to improve the outcomes for substantial clinical benefit. Here we aimed to explore the combination of vinorelbine with the second EGFR-TKI afatinib in NSCLC cells with or without EGFR mutation. The three cells of H1975, HCC827, and H460 were assessed for the combination of vinorelbine and afatinib. Vinorelbine combined with afatinib synergistically inhibited the three lung cancer cells growth without aggravating adverse effect on the normal lung cells. The combination of low doses of vinorelbine and afatinib suppressed the cancer cell proliferation by cell colony formation assay and significantly induced cell apoptosis. The anti-apoptotic proteins Bcl-xL and Bcl-2 showed significant reduction after the drug combination treatment, while the pro-apoptotic protein Bax as well as apoptosis indicators cytochrome C and cleaved PARP were observed a notable increasing. EGFR downstream pathways including AKT, ERK, JNK, and p38 were highly active and p53 was inactive in the three lung cancer cells, favoring tumor growth. The low doses of vinorelbine plus afatinib blocked the phosphorylation of AKT, ERK, JNK, and p38, but restored the expression of p53. Our findings suggested that the combination of vinorelbine and afatinib could be recommended as a therapeutic regimen for treatment of NSCLC with or without EGFR mutation.

1 January 2017 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
YTYuou Teng
Yuou Teng
LWLixin Wang
Lixin Wang
HLHuan Liu
Huan Liu
YYYuan Yuan
Yuan Yuan
QZQian Zhang
Qian Zhang
PYPeng Yu
Peng Yu